Clinical Trial Update: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial comparing rituximab and mosunetuzumab for low tumor burden follicular lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Mosunetuzumab (mosunetuzumab)
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features | Phase 3 | Status: RECRUITING